Alnylam Pharmaceuticals (ALNY) EBIT Growth (3y) (2012 - 2026)
Powered by 
Analysis
Alnylam Pharmaceuticals (ALNY) EBIT Growth (3y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -96.48% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 81.27% |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -21.57% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 44.34% |
| Mar 31, 2026 | 55.96% |
| Dec 31, 2025 | 39.22% |
| Sep 30, 2025 | 50.75% |
| Jun 30, 2025 | 56.12% |
| Mar 31, 2025 | 28.53% |
| Dec 31, 2024 | 18.54% |
| Sep 30, 2024 | 24.92% |
| Jun 30, 2024 | 32.62% |
| Mar 31, 2024 | 38.45% |
| Dec 31, 2023 | 15.69% |
| Sep 30, 2023 | 43.41% |
| Jun 30, 2023 | -4.94% |
| Mar 31, 2023 | 10.67% |
| Dec 31, 2022 | 14.15% |
| Sep 30, 2022 | -6.06% |
| Jun 30, 2022 | 6.73% |
| Mar 31, 2022 | 8.06% |
| Dec 31, 2021 | 4.07% |
| Sep 30, 2021 | 10.63% |